Table 1.
Demographic, anthropomorphic, and clinical characteristics of participants included in the analysis.
| Placebo (n = 170) | Azithromycin (n = 166) | |
|---|---|---|
| Malawi Trial Site, n (%) | 49 (28·8) | 46 (27·7) |
| Zimbabwe Trial Site, n (%) | 121 (71·2) | 120 (72·3) |
| 48 Week Data Available, n | 154 | 157 |
| 72 Week Data Available, n | 113 | 123 |
| Age, Mean (SD) | 15·3 (3·2) | 14·6 (3·2) |
| Sex Male | 82 (48·2) | 88 (53·0) |
| Height for Age z score, Mean (SD) | −2·1 (1·2) | −2·2 (1·2) |
| Weight for age z score, Mean (SD) | −2·1 (1·5) | −2·3 (1·4) |
| Indicated previous treatment for Tuberculosis, n (%) | 39 (22·9) | 58 (35·2) |
| CD4 T Cell Count, Cells/mm3 (SE) | 576·0 (354·9) | 634·1 (386·8) |
| Supressed HIV-1 Viral load (<1000 copies/ml), n (%) | 91 (53·5) | 96 (57·8) |
| HIV-1 Viral load copies/ml, Median, IQR** | 492·5 (13502·8) | 331·0 (10961·0) |
| FEV1z score, Mean (SE) | −2·0 (0·7) | −2·1 (0·7) |
| FEV1:FEV Ratio, Mean (SE) | −0·8 (1·1) | −0·7 (1·1) |
| FEV Percent Predicted, Mean (SE) | 73·1 (9·9) | 72·5 (9·9) |
| Duration on ART, Mean Years (SE) | 6·3 (3·2) | 6·5 (3·3) |
| First Line ART Regimen – ATV/LPV/PI, n (%) | 127 (74·7) | 120 (72·3) |
| Second Line ART Regimen – EFV/NVP, n (%) | 43 (25·3) | 46 (27·7) |
Table showing participant characteristics split by treatment arm. IQR = Interquartile Range, N = Number, ATV = Atazanavir, LPV = Lopinavir, PI = Protease inhibitor, EFV = Efavirenz, NVP = Nevirapine. FEV = Forced expiratory volume *One data point missing, ** Two data points missing, imputed with mean imputation.